Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00321308 · ClinicalTrials.gov registry record · Phase 2

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

A Phase 2 study, sponsored by Pfizer.

Terminated
Registry status
Phase 2
Development phase
36
Enrollment target

NCT00321308: Clinical Trial Phase 2 study, sponsored by Pfizer.

NCT00321308 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00321308, a Phase 2 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 2
Development phase
36 participants
Enrollment target

Study Summary

To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemotherapy regimen

Interventions

  • DRUG pemetrexed
  • DRUG pemetrexed + PF-3512676

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2006-09
Est. Completion 2008-01
Phase Phase 2
Pfizer

1,845 total trials

Why NCT00321308 stopped before completion

NCT00321308 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 2 interventions - of which pemetrexed is the first listed.

NCT00321308 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00321308 about?

NCT00321308 is a clinical study titled "Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer". To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemotherapy regimen

What is the current status of trial NCT00321308?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2006-09. Estimated completion is 2008-01.

What interventions are being tested in trial NCT00321308?

The interventions under investigation include: pemetrexed (DRUG), pemetrexed + PF-3512676 (DRUG).

Who is sponsoring clinical trial NCT00321308?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00321308's enrollment target sits among peer trials

36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00321308, the US trial registry maintained by the National Library of Medicine. NCT00321308 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.